AIMS: Cytological diagnosis of malignant pleural mesothelioma (MPM) is controversial, but has been used in our institution for over 30 years. To assess the role of effusion cytology in mesothelioma diagnosis we conducted an audit of pleural fluid cytology results over a 20 year period (1988-2007). METHODS: Pleural samples were received from 6285 patients; data linkage with Western Australian Cancer and Mesothelioma Registries demonstrated that 815 of these patients had a diagnosis of MPM. Cytological examination of a pleural effusion specimen had been performed in 517 (63%) of these 815 patients. RESULTS: Definitive cytological diagnosis of MPM was made in 377/517 cases, resulting in an 'absolute' sensitivity of 73%. An additional 66 patients were diagnosed as atypical/suspicious, resulting in a 'complete' sensitivity of 86%. If only biopsy/necropsy proven cases are considered, the absolute sensitivity is 68% and the complete sensitivity is 82%. There were no false positive diagnoses of malignancy; two patients with metastatic adenocarcinoma were initially diagnosed as MPM, prior to the availability of specific mesothelial markers, resulting in a positive predictive value of 99%. CONCLUSIONS: Effusion cytology is an inexpensive, minimally invasive procedure which should be included in the diagnostic work-up of cases of suspected MPM.
AIMS: Cytological diagnosis of malignant pleural mesothelioma (MPM) is controversial, but has been used in our institution for over 30 years. To assess the role of effusion cytology in mesothelioma diagnosis we conducted an audit of pleural fluid cytology results over a 20 year period (1988-2007). METHODS: Pleural samples were received from 6285 patients; data linkage with Western Australian Cancer and Mesothelioma Registries demonstrated that 815 of these patients had a diagnosis of MPM. Cytological examination of a pleural effusion specimen had been performed in 517 (63%) of these 815 patients. RESULTS: Definitive cytological diagnosis of MPM was made in 377/517 cases, resulting in an 'absolute' sensitivity of 73%. An additional 66 patients were diagnosed as atypical/suspicious, resulting in a 'complete' sensitivity of 86%. If only biopsy/necropsy proven cases are considered, the absolute sensitivity is 68% and the complete sensitivity is 82%. There were no false positive diagnoses of malignancy; two patients with metastatic adenocarcinoma were initially diagnosed as MPM, prior to the availability of specific mesothelial markers, resulting in a positive predictive value of 99%. CONCLUSIONS:Effusion cytology is an inexpensive, minimally invasive procedure which should be included in the diagnostic work-up of cases of suspected MPM.
Authors: Filip Mundt; Gustav Nilsonne; Sertaç Arslan; Karola Csürös; Gunnar Hillerdal; Huseyin Yildirim; Muzaffer Metintas; Katalin Dobra; Anders Hjerpe Journal: PLoS One Date: 2013-08-21 Impact factor: 3.240
Authors: Adam Szulkin; Rita Otvös; Carl-Olof Hillerdal; Aytekin Celep; Eviane Yousef-Fadhel; Henriette Skribek; Anders Hjerpe; László Székely; Katalin Dobra Journal: BMC Cancer Date: 2014-09-24 Impact factor: 4.430
Authors: Jenette Creaney; Amanda Segal; Nola Olsen; Ian M Dick; A W Bill Musk; Steven J Skates; Bruce W Robinson Journal: Dis Markers Date: 2014-11-23 Impact factor: 3.434
Authors: Laura Saracino; Chandra Bortolotto; Stefano Tomaselli; Elia Fraolini; Matteo Bosio; Giulia Accordino; Francesco Agustoni; David M Abbott; Emma Pozzi; Dimitrios Eleftheriou; Patrizia Morbini; Pietro Rinaldi; Cristiano Primiceri; Andrea Lancia; Patrizia Comoli; Andrea R Filippi; Giulia M Stella Journal: BMC Cancer Date: 2021-07-01 Impact factor: 4.430
Authors: Jenette Creaney; Sophie Sneddon; Ian M Dick; Hanne Dare; Neil Boudville; Arthur William Musk; Steven J Skates; Bruce W S Robinson Journal: Dis Markers Date: 2013-08-06 Impact factor: 3.434
Authors: Jenette Creaney; Ian M Dick; Tarek M Meniawy; Su Lyn Leong; Justine S Leon; Yvonne Demelker; Amanda Segal; A W Bill Musk; Y C Gary Lee; Steven J Skates; Anna K Nowak; Bruce W S Robinson Journal: Thorax Date: 2014-07-18 Impact factor: 9.139